Ho Juen Ko

P027 Infliximab in the treatment of cerebral tuberculosis paradoxical reactions with vasculitis

Ho Juen Ko, Anees Fatima, Aravinth Sivagnanaratnam, Alastair McGregor et autres

Abstract Background/Aims Tuberculosis meningitis (TBM) is associated with high morbidity and mortality. Up to 25% of patients may experience paradoxical reactions (PR) after commencing anti-TB therapy, which are exaggerated inflammatory reactions resulting in parenchymal inflammation, tuberculomas and secondary vasculitis. PR are minimised …

gb (code pays fourni par la source)

A comparison of mortality and indicators of treatment success of resuscitative endovascular balloon occlusion of aorta (REBOA): a systematic review and meta-analysis

Ho Juen Ko, Hui Fen Koo, Nina Al‐Saadi, Saied Froghi

gb (code pays fourni par la source)

Factors Affecting Domiciliary Non-Invasive Ventilation Compliance

Amar J. Shah, Katia Florman, Nitika Kaushal, Hiu Fung Kwong et autres

Few international studies have investigated factors affecting domiciliary non-invasive ventilation (D-NIV) compliance, and data from the UK are limited. We assessed compliance (defined as ≥ 4 h/night for at least 70% of the time) in a retrospective UK population study, at three …

gb (code pays fourni par la source)

PMO-14 Use of non-invasive surrogate markers to monitor vedolizumab therapy in inflammatory bowel disease

John Barragry, Konstantinos C. Fragkos, Gregory Sebepos‐Rogers, Hajeena Saravanapavan et autres

Introduction We provide long-term data on the effectiveness of Vedolizumab (VDZ) in the management of inflammatory bowel disease (IBD) by reviewing the response of surrogate markers of disease activity to VDZ therapy, including Harvey-Bradshaw Index (HBI) for Crohn’s disease (CD) and Simple …

gb (code pays fourni par la source)

PMO-12 Real-world outcomes after Vedolizumab discontinuation in a tertiary IBD cohort

Gregory Sebepos‐Rogers, Konstantinos C. Fragkos, Hajeena Saravanapavan, John Barragry et autres

Introduction Vedolizumab. (VDZ) is an α4β7 integrin antagonist licensed to treat moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD). We provide long-term real-world data on outcomes after VDZ discontinuation. Methods A consecutive cohort of 193 adult IBD patients initiated on …

gb (code pays fourni par la source)

PMO-17 Clinical predictors of Vedolizumab response in Crohn’s disease

Hajeena Saravanapavan, Gregory Sebepos‐Rogers, Konstantinos C. Fragkos, John Barragry et autres

Introduction Vedolizumab (VDZ) is an α4β7 integrin antagonist licensed for treatment of moderate to severe Crohn’s disease (CD). We provide long-term data on best predictors of clinical and corticosteroid-free response, remission and persistence from a tertiary IBD centre. Methods A consecutive cohort …

gb (code pays fourni par la source)

A retrospective study on the risk of tuberculosis in patients with rheumatoid arthritis

Tin Tsun Chung, Ho Juen Ko, Chak Sing Lau, Ho Yin Chung

hk, gb (code pays fourni par la source)

High-field-seeking Rydberg atoms orbiting a charged wire

Ho Juen Ko, S. D. Hogan

Pulsed supersonic beams of helium atoms in the high-field-seeking $52p$ Rydberg state have been guided while following helical trajectories in the electrostatic field of a charged wire suspended along the axis of a grounded cylindrical metallic tube. The operation of this electrostatic …

gb (code pays fourni par la source)